Updated Jul 16, 2026
GRAMMER ELIZABETH A has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $93K.
Elizabeth A. Grammer is a corporate director involved with biopharmaceutical companies, including Ardelyx, Inc. and Sagimet Biosciences Inc. She has participated in several SEC filings, indicating her active role in corporate governance.
| Role | Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-08-21 | ARDX | ARDELYX, INC. | S — Open-market sale | 5.8K | $5.93 | $35K |
| 2025-05-20 | ARDX | ARDELYX, INC. | S — Open-market sale | 6.0K | $4.08 | $24K |
| 2024-11-22 | ARDX | ARDELYX, INC. | S — Open-market sale | 7.0K | $4.79 | $34K |
Elizabeth A. Grammer is a corporate director involved with biopharmaceutical companies, including Ardelyx, Inc. and Sagimet Biosciences Inc. She has participated in several SEC filings, indicating her active role in corporate governance.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($93K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live GRAMMER ELIZABETH A profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.